nav menu
close nav
background
background

NEWS

9 February 2021

Akston Biosciences Completes Second Licensing and Supply Agreement with Dechra Pharmaceuticals PLC

16 January 2021

Disrupting Insulin and IGF Receptor Function in Cancer

5 January 2021

Akston and LakePharma Announce Strategic Partnership to Manufacture AKS-452

1 September 2020

TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452

22 July 2020

Akston Biosciences Receives $2.5M Milestone Payment

27 May 2020

Akston Biosciences Awarded NIDDK Phase IIb Grant

9 April 2020

Akston Biosciences Completes Series E Preferred Stock Financing

15 February 2020

Abstract P1-21-05: A novel long-acting insulin for cancer therapy reduces xenograft tumor growth

2 August 2019

Akston Biosciences Completes Licensing and Supply Agreement with Dechra Pharmaceuticals PLC

24 July 2019

Helmsley Charitable Trust and Akston Biosciences Corporation Extend Partnership